Literature DB >> 32249949

Germline mutations predisposing to melanoma.

Atrin Toussi1, Nicole Mans2, Jeanna Welborn2, Maija Kiuru1,3.   

Abstract

Nearly 15% of melanomas occur in patients with a family history and a subset of these patients have a germline mutation in a melanoma predisposing gene. CDKN2A mutations are responsible for the majority of hereditary melanoma, but many other susceptibility genes have been discovered in recent years, including CDK4, TERT, ACD, TERF2IP, POT1, MITF, MC1R, and BAP1. Additionally, melanoma risk is increased in mixed cancer syndromes caused by mutations in PTEN, BRCA2, BRCA1, RB1, and TP53. While early onset, multiple tumors, and family cancer history remain the most valuable clinical clues for hereditary melanoma, characteristic epithelioid cytology of melanocytic tumors may suggest an underlying BAP1 mutation. Herein, we review the clinical and histopathologic characteristics of melanocytic tumors associated with these germline mutations and discuss the role of genetic counseling.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CDKN2A; germline mutation; hereditary; melanocytic nevus; melanoma

Mesh:

Substances:

Year:  2020        PMID: 32249949      PMCID: PMC8232041          DOI: 10.1111/cup.13689

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  92 in total

1.  Histomorphologic spectrum of BAP1 negative melanocytic neoplasms in a family with BAP1-associated cancer susceptibility syndrome.

Authors:  Zlatko Marušić; Marija Buljan; Klaus J Busam
Journal:  J Cutan Pathol       Date:  2015-05-12       Impact factor: 1.587

2.  Malignant melanoma in xeroderma pigmentosum patients: report of five cases.

Authors:  O Kocabalkan; F Ozgür; Y Erk; K G Gürsu; Y Güngen
Journal:  Eur J Surg Oncol       Date:  1997-02       Impact factor: 4.424

Review 3.  Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature.

Authors:  Alexandra M Haugh; Ching-Ni Njauw; Jeffrey A Bubley; Anna Elisa Verzì; Bin Zhang; Emily Kudalkar; Timothy VandenBoom; Kara Walton; Brian L Swick; Raj Kumar; Huma Q Rana; Sarah Cochrane; Shelley R McCormick; Christopher R Shea; Hensin Tsao; Pedram Gerami
Journal:  JAMA Dermatol       Date:  2017-10-01       Impact factor: 10.282

4.  Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations.

Authors:  Malihe Eskandarpour; Jamileh Hashemi; Lena Kanter; Ulrik Ringborg; Anton Platz; Johan Hansson
Journal:  J Natl Cancer Inst       Date:  2003-06-04       Impact factor: 13.506

5.  Highly recurrent TERT promoter mutations in human melanoma.

Authors:  Franklin W Huang; Eran Hodis; Mary Jue Xu; Gregory V Kryukov; Lynda Chin; Levi A Garraway
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

6.  Marshaling the Translational Potential of MC1R for Precision Risk Assessment of Melanoma.

Authors:  Peter A Kanetsky; Jennifer L Hay
Journal:  Cancer Prev Res (Phila)       Date:  2017-12-15

Review 7.  MITF in melanoma: mechanisms behind its expression and activity.

Authors:  Mariusz L Hartman; Malgorzata Czyz
Journal:  Cell Mol Life Sci       Date:  2014-11-30       Impact factor: 9.261

8.  Genetic and Epigenetic Alterations of TERT Are Associated with Inferior Outcome in Adolescent and Young Adult Patients with Melanoma.

Authors:  Brittani Seynnaeve; Seungjae Lee; Sumit Borah; Yongseok Park; Alberto Pappo; John M Kirkwood; Armita Bahrami
Journal:  Sci Rep       Date:  2017-04-05       Impact factor: 4.379

9.  Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma.

Authors:  N Soufir; J J Lacapere; G Bertrand; E Matichard; R Meziani; D Mirebeau; V Descamps; B Gérard; A Archimbaud; L Ollivaud; F Bouscarat; M Baccard; G Lanternier; P Saïag; C Lebbé; N Basset-Seguin; B Crickx; H Cave; B Grandchamp
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

10.  The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma.

Authors:  F Lesueur; M de Lichy; M Barrois; G Durand; J Bombled; M-F Avril; A Chompret; F Boitier; G M Lenoir; B Bressac-de Paillerets; Monique Baccard; Bertrand Bachollet; Pascaline Berthet; Valérie Bonadona; Jean-Marie Bonnetblanc; Olivier Caron; Jacqueline Chevrant-Breton; Jean-François Cuny; Stéphane Dalle; Michèle Delaunay; Liliane Demange; Julie De Quatrebarbes; Jean-François Doré; Marc Frénay; Jean-Pierre Fricker; Marion Gauthier-Villars; Paul Gesta; Sophie Giraud; Philippe Gorry; Florent Grange; Andrew Green; Laetitia Huiart; Nicolas Janin; Pascal Joly; Delphine Kérob; Christine Lasset; Dominique Leroux; Jean-Marc Limacher; Michel Longy; Sandrine Mansard; Karine Marrou; Tanguy Martin-Denavit; Christine Mateus; Eve Maubec; Laurence Olivier-Faivre; Vincent Orlandini; Pascal Pujol; Bruno Sassolas; Dominique Stoppa-Lyonnet; Luc Thomas; Pierre Vabres; Laurence Venat; Ewa Wierzbicka; Hélène Zattara
Journal:  Br J Cancer       Date:  2008-07-08       Impact factor: 7.640

View more
  9 in total

1.  SEOM clinical guideline for the management of cutaneous melanoma (2020).

Authors:  M Majem; J L Manzano; I Marquez-Rodas; K Mujika; E Muñoz-Couselo; E Pérez-Ruiz; L de la Cruz-Merino; E Espinosa; M Gonzalez-Cao; A Berrocal
Journal:  Clin Transl Oncol       Date:  2021-03-02       Impact factor: 3.405

Review 2.  The Impact of Hyaluronan on Tumor Progression in Cutaneous Melanoma.

Authors:  Piia Takabe; Hanna Siiskonen; Aino Rönkä; Kirsi Kainulainen; Sanna Pasonen-Seppänen
Journal:  Front Oncol       Date:  2022-01-21       Impact factor: 6.244

Review 3.  Considerations for Germline Testing in Melanoma: Updates in Behavioral Change and Pancreatic Surveillance for Carriers of CDKN2A Pathogenic Variants.

Authors:  Kristen Pauley; Ambreen Khan; Wendy Kohlmann; Joanne Jeter
Journal:  Front Oncol       Date:  2022-03-16       Impact factor: 6.244

Review 4.  The spectrum of melanocytic nevi and their clinical implications.

Authors:  Nina Frischhut; Bernhard Zelger; Fiona Andre; Bettina Gudrun Zelger
Journal:  J Dtsch Dermatol Ges       Date:  2022-04       Impact factor: 5.231

5.  Association Between Telomere Length and Skin Cancer and Aging: A Mendelian Randomization Analysis.

Authors:  Nannan Son; Yankun Cui; Wang Xi
Journal:  Front Genet       Date:  2022-07-12       Impact factor: 4.772

Review 6.  Role of extracellular matrix architecture and signaling in melanoma therapeutic resistance.

Authors:  Ana Popovic; Sophie Tartare-Deckert
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

Review 7.  Cyclin-dependent kinases and rare developmental disorders.

Authors:  Pierre Colas
Journal:  Orphanet J Rare Dis       Date:  2020-08-06       Impact factor: 4.123

8.  Seed sequence polymorphism rs2168518 and allele-specific target gene regulation of hsa-miR-4513.

Authors:  Christina Kiel; Tobias Strunz; Daniele Hasler; Gunter Meister; Felix Grassmann; Bernhard H F Weber
Journal:  Hum Mol Genet       Date:  2022-03-21       Impact factor: 6.150

Review 9.  The Interplay between Nevi and Melanoma Predisposition Unravels Nevi-Related and Nevi-Resistant Familial Melanoma.

Authors:  Stefania Pellegrini; Lisa Elefanti; Luigi Dall'Olmo; Chiara Menin
Journal:  Genes (Basel)       Date:  2021-07-16       Impact factor: 4.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.